Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Study sponsor: Travere Therapeutics, Inc. · TVTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-06Actual
Enrollment · participants109Actual
Source updated2025-05-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.